

## Development of an oral EGR1-targeted candidate for atopic dermatitis



IMMUNOLOGY	Candidate
Product Type	Small molecules
Indication	Moderate to severe atopic dermatitis in adults and infants, particularly in chronic cases where existing treatment fails to control itching and inflammation
Target	EGR-1
MoA (Mechanism of Action)	Through the mechanism of allosteric inhibition, the DNA-binding ability of EGR-1 is disrupted, preventing the production of genes implicated in the pathogenesis of atopic dermatitis.
Competitiveness	<ul style="list-style-type: none"> <li>- First-in-Class</li> <li>- IT25 exhibits fewer side effects by inhibiting the transcriptional regulation of inflammatory genes, which leads to a diminished impact on the systemic immune response, and may be suitable for use in combination with existing treatment options.</li> </ul>
Development Stage	Candidate
Route of Administration	Oral

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*